Peter Marks (Jim Lo Scalzo/Pool via AP Images)
January 10, 2024 11:17 AM ESTUpdated 01:32 PM
Cell/Gene Tx
FDA+

FDA's CBER chief hints at ex­pand­ing Sarep­ta's gene ther­a­py la­bel, sends stock up 25%

Zachary Brennan

Senior Editor

De­spite a failed con­fir­ma­to­ry tri­al an­nounced in Oc­to­ber, the FDA’s Pe­ter Marks, the top reg­u­la­tor for all cell and gene ther­a­pies in the US, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times